Company intelligence / Profile preview

Infervision

Beijing, Beijing, Chinaglobal.infervision.com ↗

Ownership: Private
Employees: ~300
Development stage: Commercial

Overview

Infervision’s AI-powered platforms have received multiple regulatory clearances including FDA 510(k) for products like InferRead® CT Stroke and CT Lung. Their solutions are deployed globally across more than 25 countries and used by hundreds of hospitals for rapid detection of a range of conditions from lung cancer to stroke. Clinical results highlight improved diagnostic speed and accuracy compared to manual review[1][2][5].

Therapeutic areas: OncologyOtherRheumatologyCardiovascularNeurologyInfectious Diseases
Modalities: Device (AI-powered medical imaging software)
Industry: Medical Imaging

Partnerships

SimonMed Imaging (large US outpatient imaging provider)GE HealthcareCiscoNvidia

Beyond the preview

Go deeper on Infervision.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Infervision.

Explore the full profile